Brokers Offer Predictions for Aclaris Therapeutics, Inc.’s FY2022 Earnings (NASDAQ:ACRS)

Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) – Analysts at Cantor Fitzgerald issued their FY2022 earnings per share (EPS) estimates for Aclaris Therapeutics in a research report issued on Monday, August 1st. Cantor Fitzgerald analyst L. Chen anticipates that the biotechnology company will post earnings per share of ($1.65) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($1.49) per share. Cantor Fitzgerald also issued estimates for Aclaris Therapeutics’ FY2023 earnings at ($1.68) EPS.

Aclaris Therapeutics (NASDAQ:ACRS – Get Rating) last announced its earnings results on Wednesday, August 3rd. The biotechnology company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.05. Aclaris Therapeutics had a negative return on equity of 42.05% and a negative net margin of 1,355.98%.

Separately, William Blair restated an “outperform” rating on shares of Aclaris Therapeutics in a research note on Wednesday, May 11th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Aclaris Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $38.00.

Aclaris Therapeutics Price Performance

Aclaris Therapeutics stock opened at $18.00 on Thursday. The stock’s fifty day moving average price is $15.04 and its two-hundred day moving average price is $14.28. Aclaris Therapeutics has a one year low of $9.26 and a one year high of $19.97. The firm has a market cap of $1.20 billion, a PE ratio of -13.43 and a beta of 0.60.

Insider Buying and Selling at Aclaris Therapeutics

In other Aclaris Therapeutics news, Director Andrew N. Schiff sold 19,565 shares of the firm’s stock in a transaction on Friday, June 17th. The stock was sold at an average price of $15.14, for a total value of $296,214.10. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 6.70% of the company’s stock.

Institutional Investors Weigh In On Aclaris Therapeutics

A number of large investors have recently modified their holdings of the business. Point72 Hong Kong Ltd acquired a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at $26,000. BNP Paribas Arbitrage SA boosted its holdings in shares of Aclaris Therapeutics by 20.2% during the 4th quarter. BNP Paribas Arbitrage SA now owns 10,852 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 1,823 shares in the last quarter. Nisa Investment Advisors LLC acquired a new stake in shares of Aclaris Therapeutics during the 2nd quarter valued at $26,000. DekaBank Deutsche Girozentrale boosted its holdings in shares of Aclaris Therapeutics by 10.0% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 22,000 shares of the biotechnology company’s stock valued at $388,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Blair William & Co. IL boosted its holdings in shares of Aclaris Therapeutics by 27.4% during the 4th quarter. Blair William & Co. IL now owns 12,800 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 2,750 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Aclaris Therapeutics Company Profile

(Get Rating)

Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.